Spriewald B M, Wassmuth R, Carl H D, Köckerling F, Reichstetter S, Kleeberger A, Klein M, Hohenberger M W, Kalden J R
Institute for Clinical Immunology, Department of Medicine III, University of Erlangen-Nürnberg, Erlangen, Germany.
Transplantation. 1998 Jul 15;66(1):77-83. doi: 10.1097/00007890-199807150-00012.
Microchimerism after liver transplantation is a readily observed phenomenon. The immunological implications, however, remain unclear. Moreover, methodological approaches and their detection limits in the study of allogeneic microchimerism have not been studied in detail.
Therefore, the aim of this study was to evaluate the single-step and nested formats of the polymerase chain reaction/sequence-specific priming (PCR-SSP) approach under standardized conditions. For that purpose, a panel of recombinant plasmid clones was generated by PCR cloning. The panel contained the allelic sequences of the second exon of DRB1 covering all DR specificities on a low-resolution level. Using this panel, limiting dilution assays for various DR sequences in the presence and absence of competitor DNA were carried out to determine the minimal number of copies required for detection by single-step and nested PCR-SSP. Subsequently, 22 liver transplant recipients were analyzed in a retrospective study for the presence of allogeneic microchimerism by nested PCR-SSP.
Although at least 10 copies of template DNA could be detected by nested PCR-SSP overall, single-step PCR-SSP was on average 10(2) to 10(3) times less sensitive. Upon the addition of human competitor DNA, the detection limits decreased on average by a factor of 10. In addition, sequence-specific differences in amplification efficiency could be appreciated. Using nested PCR-SSP, peripheral blood allogeneic microchimerism could be observed in 17 of 22 HLA-DR-mismatched liver recipients. Recombinants representing recipient DRB1 specificities were used to exclude false-positive results by lack of cross-reactivities of the donor-specific primers and to evaluate negative results due to sample-related reduced amplification efficiencies in microchimerism-negative recipients. In donor/recipient combinations that differed by at least one DR specificity, allogeneic microchimerism was seen in 87.5% of the cases. In five chimerism-negative cases, sample-related problems were detected in two cases.
The optimization and standardization of the detection of genomic HLA sequences at low copy number may be greatly facilitated using a clonal reference system. Furthermore, a clonal reference system may be used to conduct cross-priming experiments to exclude false-positive results and may allow the determination of sample-specific detection limits for donor-derived HLA-DR specificities in chimerism-negative patients. Our evaluation of the PCR-SSP approach for the study of allogeneic microchimerism indicated that nested PCR-SSP provides the most sensitive format when HLA sequences are targeted. Yet, the detection sensitivity may vary between individual alleles and specificities. Allogeneic microchimerism in liver recipients can be observed in the majority of patients. However, the detection may be subject to the degree of mismatching, the HLA-DR alleles involved, and sample-related impaired PCR amplification efficiency.
肝移植后的微嵌合体现象是一种易于观察到的现象。然而,其免疫学意义仍不明确。此外,在异基因微嵌合体研究中的方法学及其检测限尚未得到详细研究。
因此,本研究的目的是在标准化条件下评估聚合酶链反应/序列特异性引物(PCR-SSP)方法的单步和巢式形式。为此,通过PCR克隆生成了一组重组质粒克隆。该组包含DRB1第二外显子的等位基因序列,在低分辨率水平上涵盖了所有DR特异性。使用该组,在有和没有竞争DNA的情况下对各种DR序列进行有限稀释分析,以确定单步和巢式PCR-SSP检测所需的最小拷贝数。随后,在一项回顾性研究中,通过巢式PCR-SSP对22例肝移植受者进行分析,以检测异基因微嵌合体的存在。
尽管总体上巢式PCR-SSP至少可检测到10个拷贝的模板DNA,但单步PCR-SSP的敏感性平均低10²至10³倍。加入人竞争DNA后,检测限平均降低10倍。此外,可观察到扩增效率的序列特异性差异。使用巢式PCR-SSP,在22例HLA-DR不匹配的肝移植受者中,有17例观察到外周血异基因微嵌合体。代表受者DRB1特异性的重组体用于通过供体特异性引物缺乏交叉反应性来排除假阳性结果,并评估微嵌合体阴性受者中由于样本相关的扩增效率降低导致的阴性结果。在至少有一个DR特异性不同的供体/受者组合中,87.5%的病例观察到异基因微嵌合体。在5例微嵌合体阴性病例中,2例检测到样本相关问题。
使用克隆参考系统可极大地促进低拷贝数基因组HLA序列检测的优化和标准化。此外,克隆参考系统可用于进行交叉引物实验以排除假阳性结果,并可确定嵌合体阴性患者中供体来源的HLA-DR特异性的样本特异性检测限。我们对用于异基因微嵌合体研究的PCR-SSP方法的评估表明,当靶向HLA序列时,巢式PCR-SSP提供了最敏感的形式。然而,检测敏感性可能因个体等位基因和特异性而异。大多数肝移植受者可观察到异基因微嵌合体。然而,检测可能受不匹配程度、所涉及的HLA-DR等位基因以及样本相关的PCR扩增效率受损的影响。